{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:59:54Z","timestamp":1785149994597,"version":"3.55.0"},"reference-count":30,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy associated with substantial morbidity and mortality. This systematic review evaluates the effects of tafamidis on echocardiographic parameters, cardiac biomarkers, functional outcomes, mortality, and safety in patients with ATTR-CM. Methods: This systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420261391553). PubMed, Embase, and Web of Science were searched through 20 March 2026. Eligible studies included adults with ATTR-CM treated with tafamidis and reporting, echocardiographic, biomarker, functional, mortality, or safety outcomes. Randomized controlled trials and observational studies were included. Risk of bias was assessed using the Cochrane RoB 2 tool and Newcastle\u2013Ottawa Scale. Due to substantial heterogeneity, a narrative synthesis was performed. Results: Seventeen studies were included with a total of 1890 patients. Tafamidis treatment was potentially associated with stabilization of global longitudinal strain, preservation of functional status, and lower all-cause mortality compared with untreated or control cohorts. Biomarker findings, including N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT), were heterogeneous and did not demonstrate a consistent pattern of improvement. Functional outcomes, including New York Heart Association (NYHA) class, 6-minute walk distance (6MWT), National Amyloidosis Center (NAC) staging, and quality-of-life measures, suggested slower clinical deterioration among treated patients. Limited available safety data indicated that tafamidis was generally well tolerated, with no major safety concerns identified. Conclusions: Current evidence may suggest that tafamidis slows disease progression and may potentially be associated with improved survival in ATTR-CM. Further prospective studies with standardized outcome reporting are needed. Evidence was limited by heterogeneity in study design, outcome reporting, and follow-up duration, with most included studies being observational.<\/jats:p>","DOI":"10.3390\/jcm15155832","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:47:41Z","timestamp":1785145661000},"page":"5832","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7642-5716","authenticated-orcid":false,"given":"Ameen","family":"Nasser","sequence":"first","affiliation":[{"name":"Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9133-4935","authenticated-orcid":false,"given":"Mateusz","family":"Michalczak","sequence":"additional","affiliation":[{"name":"Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Malkowski","sequence":"additional","affiliation":[{"name":"Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3489-5063","authenticated-orcid":false,"given":"Wiktoria Ma\u0142gorzata","family":"Zgoda","sequence":"additional","affiliation":[{"name":"Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Michalczak","sequence":"additional","affiliation":[{"name":"Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2493-5911","authenticated-orcid":false,"given":"Anna","family":"\u017b\u0105d\u0142o","sequence":"additional","affiliation":[{"name":"Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0836-1877","authenticated-orcid":false,"given":"Tomasz","family":"Tokarek","sequence":"additional","affiliation":[{"name":"Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland"},{"name":"Center for Invasive Cardiology, Electrotherapy and Angiology, 33-300 Nowy Sacz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Movila, D.E., Motofelea, A.C., Cozma, D., Albai, O., Sima, A.C., Andor, M., Ciocarlie, T., and Dragan, S.R. (2025). Cardiac Amyloidosis: A Narrative Review of Diagnostic Advances and Emerging Therapies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051230"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s43044-024-00517-y","article-title":"Tafamidis therapy in transthyretin amyloid cardiomyopathy: A narrative review from clinical trials and real-world evidence","volume":"76","author":"Ogieuhi","year":"2024","journal-title":"Egypt. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"46181","DOI":"10.31083\/RCM46181","article-title":"Transthyretin Cardiac Amyloidosis and Heart Failure: State-of-the-Art Review and Practice Guidance","volume":"26","author":"Bukhari","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40119-024-00365-6","article-title":"Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIATM LRx)","volume":"13","author":"Attal","year":"2024","journal-title":"Cardiol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_7","unstructured":"Wells, G., O\u2019Connell, D., Peterson, J., Welch, M., Losos, M., and Tugwell, P. (2020). The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses, Ottawa Hospital Research Institute. Available online: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale."},{"key":"ref_8","unstructured":"Sahu, V. (2026). Critiplot: A Critical Appraisal Plot Visualiser for Risk of Bias in Systematic Reviews and Meta-Analyses, Version v2.1.1, Zenodo."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00392-022-02035-w","article-title":"Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging","volume":"112","author":"Chamling","year":"2023","journal-title":"Clin. Res. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1253\/circrep.CR-25-0066","article-title":"Comparing Effects of Tafamidis in Controlling Left Ventricular and Left Atrial Strains in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy","volume":"7","author":"Eguchi","year":"2025","journal-title":"Circ. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy","volume":"30","author":"Rettl","year":"2022","journal-title":"Amyloid"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/ehf2.14380","article-title":"Clinical Characteristics, Outcome, and Therapeutic Effect of Tafamidis in Wild-Type Transthyretin Amyloid Cardiomyopathy","volume":"10","author":"Takashio","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00392-025-02691-8","article-title":"CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis","volume":"115","author":"Zlibut","year":"2026","journal-title":"Clin. Res. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4070\/kcj.2025.0196","article-title":"Real-World Efficacy of Tafamidis in Korean ATTR-CM Patients: A Retrospective Observational Strain Analysis","volume":"56","author":"Shin","year":"2026","journal-title":"Korean Circ. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e034518","DOI":"10.1161\/JAHA.124.034518","article-title":"Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients with Transthyretin Amyloid Cardiomyopathy","volume":"13","author":"Kuyama","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ney, S., Gertz, R.J., Pennig, L., Nies, R.J., Holtick, U., V\u00f6lker, L.A., Wunderlich, G., Seuthe, K., Hohmann, C., and Metze, C. (2024). Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010284"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1253\/circj.CJ-24-0733","article-title":"Long-Term Effect of Tafamidis on Clinical Parameters and Prognostic Predictors in Patients with Transthyretin Amyloid Cardiomyopathy","volume":"89","author":"Kuyama","year":"2025","journal-title":"Circ. J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Dobner, S., Zarro, S., Wieser, F., Kassar, M., Alaour, B., Wiedemann, S., Bakula, A., Caobelli, F., Stortecky, S., and Gr\u00e4ni, C. (2024). Effect of Timely Availability of TTR-Stabilizing Therapy on Diagnosis, Therapy, and Clinical Outcomes in ATTR-CM. J. Clin. Med., 13.","DOI":"10.20944\/preprints202408.1418.v1"},{"key":"ref_20","first-page":"580","article-title":"Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients with Transthyretin Amyloid Cardiomyopathy","volume":"3","author":"Falk","year":"2021","journal-title":"J. Am. Coll. Cardiol. CardioOnc."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Palmiero, G., Monda, E., Verrillo, F., Dongiglio, F., Cirillo, C., Caiazza, M., Rubino, M., Cirillo, A., Fusco, A., and Diana, G. (2024). Impact of Tafamidis on Delaying Clinical, Functional, and Structural Cardiac Changes in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133730"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"Eur. Heart J.\u2014Cardiovasc. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Shahi, K., Miller, R.J.H., Dykstra, S., Feng, Y., Howlett, J.G., Jimenez-Zepeda, V., Veenhuyzen, J., White, J.A., and Fine, N.M. (2024). Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center Experience. J. Clin. Med., 13.","DOI":"10.3390\/jcm13185490"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.33963\/v.phj.109824","article-title":"Multicenter study of patients with transthyretin cardiac amyloidosis in Poland: Clinical characteristics, genotyping, electrocardiographic features, outcome predictors, and tafamidis treatment outcomes","volume":"84","author":"Grzybowski","year":"2026","journal-title":"Pol. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00330-025-11792-x","article-title":"Serial extracellular volume quantification using cardiac magnetic resonance imaging in transthyretin amyloidosis patients treated with tafamidis","volume":"36","author":"Duca","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"ref_27","first-page":"685","article-title":"Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy","volume":"13","author":"Griffin","year":"2025","journal-title":"J. Am. Coll. Cardiol. Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.15420\/usc.2025.11","article-title":"Transthyretin Amyloid Cardiomyopathy: The Plot Thickens as Novel Therapies Emerge","volume":"19","author":"Dimza","year":"2025","journal-title":"US Cardiol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40119-025-00424-6","article-title":"Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy","volume":"14","author":"Margolin","year":"2025","journal-title":"Cardiol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e38767","DOI":"10.1097\/MD.0000000000038767","article-title":"A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"103","author":"Olatunji","year":"2024","journal-title":"Medicine"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/5832\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:07:26Z","timestamp":1785146846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/5832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":30,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15155832"],"URL":"https:\/\/doi.org\/10.3390\/jcm15155832","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}